nContact

Morrisville, United States Founded: 2005 • Age: 21 yrs Acquired By AtriCure
Epicardial ablation devices

About nContact

nContact is a Healthcare company based in Morrisville (United States) founded in 2005, and was acquired by AtriCure in October 2015. Epicardial ablation devices. nContact has raised $67.67 million across 8 funding rounds from investors including AtriCure, Hercules Capital and Harbert Management. The company has 14 employees. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is NCONTACT SURGICAL, INC. Its competitors include AtriCure, AtaCor Medical and Kestra Medical Technologies; 2 of its 3 listed competitors have raised funding.

Company details

nContant has developed the EPi-Sense and Numeris Coagulation System and VisiTrax epicardial ablation device for treatment of atrial fibrillation. The EPi-Sense and Numeris Coagulation System with VisiTrax have CE Mark Approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. It integrates suction, perfusion, and radiofrequency energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart. Numeris with VisiTrax is also indicated for endoscopic coagulation of cardiac tissue in the United States.

  • Headquarters Morrisville, United States
  • Employees 14
  • Stage Acquired
  • Sectors
    Healthcare
  • Website ncontact.us
  • Acquired by AtriCure (Oct 2015)
  • Legal Name Ncontact Surgical, Inc.
Key Metrics
  • Total Equity Funding
    $67.67M (USD)

    in 8 rounds

  • Latest Funding Round
    $20M (USD), Series D

    Nov 2014

  • Investors
    AtriCure

    & 7 more

  • Employee Count
    14
  • Acquired by
    AtriCure

    (Oct 2015)

Funding Insights of nContact

nContact has successfully raised a total of $67.67M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $20 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $67.67M
  • Total Rounds 8
  • Last Round Series D β€” $20M
  • First Round $7.5M

    (Sep 2006)

  • Investors Count 7

All 8 funding rounds of nContact with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2014$20MSeries D––
Mar 2013$6.74MSeries D––
–
Jan 2012$433,761Debt – Conventional––
–
Nov 2010$16.15MSeries C––
Aug 2010$4MSeries C––
–
Apr 2009$4.79MSeries B––
–
Nov 2007$8.5MSeries B––
–
Sep 2006$7.5MSeries A––
Valuation history

8 investors in total: 8 institutional.

Investors in nContact

nContact has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include AtriCure, Hercules Capital and Harbert Management.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture debt financing is provided to companies in multiple sectors.
2003htgc.comPalo Alto, United States
Infrastructure, hedge, private equity, and debt fund focused on multiple sectors
1993harbert.netBirmingham, United States
finistere.com
Early-stage life sciences and tech focused VC firm funding companies in the US
intersouth.comDurham, United States
masseyburch.com
Seed and early stage tech and life sciences focused VC firm funding companies in the US and Europe
talloakscapital.comCharlottesville, United States
FinTech & Media focused seed and early stage VC firm investing in the US
villageventures.comWilliamstown, United States
Cardiac ablation and occlusion devices for atrial fibrillation are provided.
2000atricure.comMason, United States
Premium access

Investor details for nContact

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of nContact

4 dated milestones of nContact across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded nContact is founded.
  2. Funding First funding round of $7.5M.
  3. Funding Latest funding round, Series D, of $20.0M.
  4. Exit Acquired by AtriCure.

Competitors of nContact

nContact has 3 listed competitors in our database, 2 of them funded. They include AtriCure, AtaCor Medical and Kestra Medical Technologies.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
atricure.com2000Mason, United States1,874
Cardiac ablation and occlusion devices for atrial fibrillation are provided.
atacor.com2014San Clemente, United States$136.8M15
An implantable pacemaker system is developed for cardiac pacing therapy.
kestramedical.com2014Kirkland, United States$196M118
Medical devices are developed to support cardiovascular patients at risk.
Premium access

Detailed competitors of nContact

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Cardiac and Vascular Disorders

3 companies that operate in the same segment as nContact (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Gene-editing therapies for coronary artery disease are developed.
2018Cambridge, Massachusetts, United StatesUSD 215.5 M255
Cardiac monitoring devices and applications are provided for heart health.
2010Mountain View, California, United StatesUSD 114.38 MUSD 6.18 M67
Therapies for lowering low-density lipoprotein cholesterol levels are developed.
1998Ann Arbor, Michigan, United StatesUSD 129.7 MUSD 332.31 M304
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about nContact

nContact was founded in 2005 and raised its 1st funding round 1 year after it was founded.

nContact is headquartered in Morrisville, United States.

nContact is a funded company, having raised a total of $67.67M across 8 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on Sep 2006.

nContact has 14 employees.

nContant has developed the EPi-Sense and Numeris Coagulation System and VisiTrax epicardial ablation device for treatment of atrial fibrillation. The EPi-Sense and Numeris Coagulation System with VisiTrax have CE Mark Approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. It integrates suction, perfusion, and radiofrequency energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart. Numeris with VisiTrax is also indicated for endoscopic coagulation of cardiac tissue in the United States.

nContact's top competitors include AtaCor Medical, AtriCure and Kestra Medical Technologies.

nContact has 8 investors. Key investors include AtriCure, Hercules Capital, Harbert Management, Finistere Ventures, and Intersouth Partners.

nContact operates through Ncontact Surgical, Inc..

Yes. nContact was acquired by AtriCure in October 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available